Abstract: Isocitrate dehydrogenase (IDH) is an important metabolic enzyme involved in the tricarboxylic acid cycle. In recent years, IDH has become the most frequent tumor metabolic mutation gene in acute myeloid leukemia (AML). Unlike other mutations, it gains new functions which can catalyze α-ketoglutarate (α-KG) to produce the tumor metabolite D-2-hydroxyglutarate (D-2-HG). The increased D-2-HG in the cells can affect bone marrow cell differentiation and proliferation and induce myeloid tumorsthe genetic controls, cell signaling, bone marrow microenvironment changes and other ways. Currently, the new IDH2 inhibitors AG-221 and IDH1 inhibitors become the first-line drugs targeted therapy in patients with IDH mutations in AML. This paper focused on the mutation of IDH and its mutation characteristics, the formation mechanism of AMLthe metabolites producedmutation, the metabolic pathway of tumor metabolites and the research progress of IDH inhibitors.

Key words: isocitrate dehydrogenase (IDH), gene mutation, acute myeloid leukemia (AML), tumor metabolites, D-2-hydroxyglutarate (D-2-HG), isocitrate dehydrogenase inhibitor